Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

45.19 -4.42 (-8.91%)
Streaming Delayed Price Updated: 3:21 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Avis Budget, Scholastic And Other Big Gainers From Monday ↗
U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... 
Via Benzinga
News headline image
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge ↗
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. 
Via Benzinga
News headline image
Vaxcyte Shares Surge As Its Pneumococcal Vaccine On Par With Pfizer's Shot In Study ↗
 
Via Benzinga
News headline image
Why Is Tricida (TCDA) Stock Down 90% Today? ↗
Tricida (TCDA) stock is falling on Monday following the release of poor results from a Phase 3 chronic kidney disease clinical trial. 
Via InvestorPlace
News headline image
How Is The Market Feeling About Vaxcyte? ↗
Vaxcyte's (NASDAQ:PCVX) short percent of float has risen 22.85% since its last report. The company recently reported that it has 2.48 million shares sold short, which is 5.43% of all regular shares... 
Via Benzinga
News headline image
Why Is Vaxcyte (PCVX) Stock Up 70% Today? ↗
Vaxcyte (PCVX) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. 
Via InvestorPlace
News headline image
US Stocks Mixed; Dow Jumps 200 Points ↗
U.S. stocks traded mixed this morning, with the Dow Jones surging around 200 points on Monday. 
Via Benzinga
News headline image
Vaxcyte Shares Are Soaring: Here's Why ↗
Vaxcyte Inc (NASDAQ: PCVX) shares are trading higher Monday after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Applied Genetic Techs (NASDAQ:AGTC) shares moved upwards by 62.0% to $0.39 during Monday's pre-market session. The company's market cap stands at $26.3 million. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
News headline image
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Expands Executive Leadership Team with Key Appointments
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013 ↗
Vaxcyte (NASDAQ: PCVX) has completed patient enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is its lead, 24-valent pneumococcal conjugate vaccine... 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
News headline image
Vaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study ↗
Vaxcyte (NASDAQ: PCVX) completed patient enrollment in the Phase 2 portion of the ongoing Phase 1/2 proof-of-concept study evaluating VAX-24 in healthy adults 50 to 64 years of age. 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Stealth BioTherapeutics (NASDAQ:MITO 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Rockwell Medical (NASDAQ:RMTI) st... 
Via Benzinga
News headline image
26 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Dave Inc. (NASDAQ: DAVE) gained 29.4% to $6.73. Takung Art Co., Ltd. (NASDAQ: TKAT) shares gained 18.6% to $4.1499. Traders are circulating earlier news that China is... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
News headline image
Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate ↗
Vaxcyte Inc (NASDAQ: PCVX) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share,... 
Via Benzinga
News headline image
20 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Mostly Flat Ahead Of PPI, Jobless Claims ↗
Pre-open movers U.S. stock futures traded mostly flat in early pre-market trade after closing slightly higher in the previous session. Investors are awaiting earnings results from... 
Via Benzinga
News headline image
5 Stocks To Watch For January 13, 2022 ↗
Some of the stocks that may grab investor focus today are: Wall Street expects Delta Air Lines, Inc. (NYSE: DAL) to report quarterly earnings at $0.13 per share on revenue of $... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Biomerica (NASDAQ:BMRA) stock inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.